Aldeyra Therapeutics Inc. Company Profile
NASDAQ: ALDXHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Aldeyra Therapeutics at a glance
Aldeyra Therapeutics Inc. (NASDAQ: ALDX) is a Biotechnology company in the Healthcare sector headquartered in Lexington, MA. Aldeyra Therapeutics is led by Dr. Todd C. Brady M.D., Ph.D. and employs about 6 people. The company's shares have traded publicly since 2014.
At a market capitalization of $57.8 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001341235, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Aldeyra Therapeutics do?
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Aldeyra Therapeutics Inc.
- Ticker
- NASDAQ: ALDX
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Todd C. Brady M.D., Ph.D.
- Employees
- 6
- Headquarters
- 131 Hartwell Avenue, Lexington, MA, United States
- Phone
- 781 761 4904
- Website
- aldeyra.com
- IPO year
- 2014
- Market cap
- $57.83M
- SEC CIK
- 0001341235
Companies similar to Aldeyra Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BOLDBoundless Bio Inc. | 2.58 | -2.27% | $58.69M | vs ALDX |
| IBIOiBio Inc. | 0.92 | -8.91% | $59.16M | vs ALDX |
| XLOXilio Therapeutics Inc. | 9.01 | 0.00% | $59.29M | vs ALDX |
| KLRSKalaris Therapeutics Inc. | 2.50 | -2.34% | $59.51M | vs ALDX |
| INKTMiNK Therapeutics Inc. | 11.00 | -3.68% | $56.13M | vs ALDX |
| GUTSFractyl Health Inc. | 4.23 | -6.42% | $56.11M | vs ALDX |
| ATHEAlterity Therapeutics Limited ADR | 3.07 | -7.53% | $55.90M | vs ALDX |
| MREOMereo BioPharma Group plc ADR | 0.3752 | +6.35% | $59.92M | vs ALDX |